| Old Articles: <Older 621-630 Newer> |
|---|
 |
Fast Company
April 2002
Bill Breen |
High Stakes, Big Bets Tom Burbage and his 500-person team at Lockheed Martin went after the biggest military deal in U.S. history -- and scored a $200 billion victory: a contract to build the Joint Strike Fighter. They didn't play it safe; they played to win...   |
Fast Company
April 2002
Keith H. Hammonds |
No Risk, No Reward Nine amazing and instructive lessons on the power of breaking the mold, the genius of the unexpected move, the thrill of standing out from the crowd, and the virtues -- yes, virtues -- of conservatism... |
Fast Company
April 2002
George Anders |
What If Carly Were a Man? The dirty little secret of Carly Fiorina (and every other woman CEO, for that matter): They're held to a different standard than guys... |
CIO
March 15, 2002
Stephanie Overby |
The Commando CEO Guy Haddleton, CEO of Adaytum, a Minneapolis-based software company he founded 11 years ago, served in the New Zealand Army for eight years in the 1970s and early 1980s. He says his years in the special forces provided valuable lessons for business -- and for life... |
IndustryWeek
April 1, 2002
Richard Osborne |
New Product Development -- Lesser Royals The customer may be king, but too often he's given less than the royal treatment... |
New Architect
April 2002
Meg Hourihan |
Understand Your Employees Better Tom DeMarco and Timothy Lister's Peopleware: Productive Projects and Teams demonstrates how managers can improve team building, the overall office environment, and workplace productivity... |
| Knowledge@Wharton |
Re-examining Stock Options as a Way to Compensate Executives Now that an underperforming stock market and the excesses of Enron have focused new attention on the use and abuse of stock options as a way to incentivize senior managers, what changes, if any, should companies make in their design of compensation packages? |
| Knowledge@Wharton |
The Benefits Are Mutual in New Wave of Biotech/Pharma Alliances The spat that erupted between pharma giant Bristol-Myers Squibb and biotech firm ImClone Systems over their partnership to develop a new cancer drug put the structure of alliances between discovery research firms and big drug makers under a microscope... |
| Knowledge@Wharton |
Showdown in Silicon Valley: Will Fiorina or Hewlett Win the Battle for H-P Shareholders' Votes? The showdown of Fiorina vs. Hewlett in Silicon Valley has been one nasty, bare-knuckle fight for the hearts and minds of 900,000 shareholders... |
| Knowledge@Wharton |
Bringing Good Things to GE: Now It's Jeff Immelt's Turn At General Electric Co. managers are groomed for meticulous corporate planning. But in his first months as chief executive of the world's most valuable company, Jeffrey R. Immelt has had more than his share of surprises... |
| <Older 621-630 Newer> Return to current articles. |
